JPMorgan analyst Brian Cheng lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $29 from $30 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1 report. It views Kyverna’s progress around the rolling application in stiff person syndrome positively.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
- Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
- Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
- 3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
- Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target